Skip to main content

Advertisement

SpringerLink
Log in

Patients With Positive Axillary Lymph Nodes: How to Use Genomic Assays

  • Breast Cancer (CI Falkson, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The treatment of breast cancer is continually evolving. Standard treatment for early stage, node positive breast cancer has included adjuvant chemotherapy. As we learn more about differences in a tumor’s genetic makeup that result in different patterns of recurrence and survival, we are starting to include gene expression in addition to the routine clinical and pathological factors when we make treatment recommendations. For lymph node negative, early stage breast cancer, there are two genomic assays in routine use to predict prognosis and benefit from adjuvant chemotherapy. There is emerging data to support that the same tests may also predict prognosis and chemotherapy benefit, or lack thereof, in lymph node positive tumors. Currently there are no standard of care and this is an area in which more research is being done. Given that the biology of breast tumors is independent of nodal status, there are certainly cases of node positive early stage breast cancer where clinicians can feel comfortable making treatment decisions based on genomic assays. These include women with micrometastases in the lymph nodes or those with one to three positive lymph nodes. Currently, the genomic assays are limited to use in tumors that are estrogen receptor positive. It is still clearly the standard of care to administer chemotherapy to estrogen receptor negative, lymph node positive tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.

    Article  PubMed  CAS  Google Scholar 

  2. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–7.

    Article  PubMed  CAS  Google Scholar 

  3. Page DL. Prognosis and breast cancer recognition of lethal and favorable prognostic types. Am J Surg Pathol. 1991;15:334–49.

    Article  PubMed  CAS  Google Scholar 

  4. Rosen PP, Groshen S, Saigo PE, et al. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow up of 18 years. J Clin Oncol. 1989;7:1239–51.

    PubMed  CAS  Google Scholar 

  5. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.

    Article  Google Scholar 

  6. Joensuu H, Pylkkanen L, Toikkanen S. Long-term survival in node-positive breast cancer treated by locoregional therapy alone. Br J Cancer. 1998;78:795–9.

    Article  PubMed  CAS  Google Scholar 

  7. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Version 2.2011. Available at http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed December 2011.

  8. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.

    Article  PubMed  CAS  Google Scholar 

  9. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxfien-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.

    Article  PubMed  CAS  Google Scholar 

  10. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–34.

    Article  PubMed  CAS  Google Scholar 

  11. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 Update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.

    Article  PubMed  CAS  Google Scholar 

  12. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319–29.

    Article  PubMed  CAS  Google Scholar 

  13. Cobleigh MA, Tabesh B, Bitterman P, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005;11:8623–31.

    Article  PubMed  CAS  Google Scholar 

  14. Albain K, Barlow W, Shak S, et al. Prognositc and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, estrogen receptor positive breast cancer on chemotherapy: A retrospective analysis of a randomized trial. Lancet Oncol. 2010;11:55–65.

    Article  PubMed  CAS  Google Scholar 

  15. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene Recurrence Score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC Study. J Clin Oncol. 2010;28:1829–34.

    Article  PubMed  Google Scholar 

  16. van’t Veer LJ, Dai H, van de Vijver, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6.

    Article  Google Scholar 

  17. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009.

    Article  PubMed  Google Scholar 

  18. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. J Clin Oncol. 2001;19:3817–27.

    PubMed  CAS  Google Scholar 

  19. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst. 2001;93:979–89.

    Article  PubMed  CAS  Google Scholar 

  20. Buyse M, Loi S, van’t Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;98:1183–92.

    Article  PubMed  CAS  Google Scholar 

  21. Adjuvant! Online. Available at http://www.adjuvantonline.com. Accessed December 2011.

  22. Bueno-de-Mesquita JM, Linn SC, Keijzer R, et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat. 2009;117:483–95.

    Article  PubMed  CAS  Google Scholar 

  23. Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2010;119:551–8.

    Article  PubMed  Google Scholar 

  24. Knauer M, Mook S, Rutgers EJ, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat. 2010;120:655–61.

    Article  PubMed  CAS  Google Scholar 

  25. Mook S, Schmidt MK, Viale G, et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat. 2009;116:295–302.

    Article  PubMed  CAS  Google Scholar 

  26. Weigelt B, Wessels LF, Bosma AJ, et al. No common denominator for breast cancer lymph node metastasis. Br J Cancer. 2005;93:924–32.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Rush University Medical Center, 1725 W. Harrison St, Suite 809, Chicago, IL, 60612, USA

    Ruta Rao MD

Authors
  1. Ruta Rao MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ruta Rao MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rao, R. Patients With Positive Axillary Lymph Nodes: How to Use Genomic Assays. Curr. Treat. Options in Oncol. 13, 240–248 (2012). https://doi.org/10.1007/s11864-012-0187-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-012-0187-3

Keywords

Search

Navigation